Real-world Elexacaftor/Tezacaftor/Ivacaftor(ETI) changes prospective sputum collection and microbiological reporting in a single centre pilot CF cohort. - Adult Cystic Fibrosis Conference, 2023

Diagnostics and treatment

Chair(s): Isabelle Fajac, Mirjam Stahl

Session type: Oral presentation

Real-world Elexacaftor/Tezacaftor/Ivacaftor(ETI) changes prospective sputum collection and microbiological reporting in a single centre pilot CF cohort.

Kevin Frederick Deasy

EVENTS HOME

e-poster
Abstract

Previous presentation

Next presentation

Session content

Late diagnosed homozygous delF508 patients - is it really rare?

Guergana Petrova

CF diagnosed at the sixth decade of life

Guergana Petrova

e-poster

Exploring the knowledge of genetics laboratories on CFTR modulator therapy eligibility: findings and reflections during external quality assessment

Nele Laudus

To treat or not to treat? When CF is a CF

Guergana Petrova

Real-world Elexacaftor/Tezacaftor/Ivacaftor(ETI) changes prospective sputum collection and microbiological reporting in a single centre pilot CF cohort.

Kevin Frederick Deasy

e-poster

Clinical, radiological and systemic inflammatory outcomes in real-world Kaftrio study (CORK2) in CF patients homozygous for Phe508del mutation.

Hisham I S Ibrahim

A case of cystic fibrosis diagnosed at twenty years old

Aytekin Idikut

e-poster

Initial experiences in treatment with modulatory therapy in patients with Cystic Fibrosis in North Macedonia

Sonja Momchilovikj

e-poster

Even grandparents can be diagnosed with Cystic Fibrosis!

Giulia Orpheu

e-poster

Is there a role for sweat chloride levels as a marker of clinical response to Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis patients?

Elsa Guerreiro Da Cunha Fragoso

e-poster

CDN Connection Issue

#{title}